Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 1, 2014, Pages 85-92

  Maasoumy, B ^a   Cobb, B ^b   Bremer, B ^a   Luk, K ^b   Halfon, P ^c   Aslam, S ^b   Manns, M P ^a   Cornberg, M ^a   Wedemeyer, H ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b ROCHE MOLECULAR SYSTEMS   (United States)

^c Hospital Ambroise Pare   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; HCV RNA TESTING; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; MIDDLE AGED; PREDICTIVE VALUE; PRIORITY JOURNAL; RELIABILITY; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; VIROLOGY; VIRUS DETECTION; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TREATMENT FAILURE; VIREMIA;

EID: 84889669157     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12544     Document Type: Article

References (15)

1. EASL Clinical Practice Guidelines. Management of hepatitis C virus infection. J Hepatol 2011; 55: 245-64.
2. Maasoumy B, Wedemeyer H,. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 2012; 26: 401-12.
3. Hanafiah KM, Groeger J, Flaxman AD, Wiersma ST,. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to hepatitis C virus seroprevalence. Hepatology 2012; 57: 1333-42.
4. Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM,. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012; 56 (Suppl. 1): S88-100.
5. Dusheiko G, Wedemeyer H,. New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye. Gut 2012; 61: 1647-52.
6. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB,. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-44.
7. Sarrazin C, Berg T, Cornberg M, et al,. [Expert opinion on boceprevir-and telaprevir-based triple therapies of chronic hepatitis C]. Z Gastroenterol 2012; 50: 57-72.
8. Harrington PR, Zeng W, Naeger LK,. Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. Hepatology 2012; 55: 1048-57.
9. Chevaliez S, Pawlotsky JM,. How to use virological tools for optimal management of chronic hepatitis C. Liver Int 2009; 29 (Suppl. 1): 9-14.
10. Chevaliez S, Pawlotsky JM,. Virological techniques for the diagnosis and monitoring of hepatitis B and C. Ann Hepatol 2009; 8: 7-12.
11. Zitzer H, Heilek G, Truchon K, et al,. Second-generation Cobas AmpliPrep/Cobas TaqMan HCV quantitative test for viral load monitoring: a novel dual-probe assay design. J Clin Microbiol 2013; 51: 571-7.
12. Wedemeyer H, Kessler HH, Michel-Treil V, et al,. The ExPECT study: an international multicenter clinical trial evaluating low HCV RNA viremia with the COBAS AmpliPrep/COBAS TaqMan HCV Test, v2.0 compared to assays used in routine clinical practise and in drug trials. Hepatology 2012; 56 (Suppl.): 676A-7A.
13. Maasoumy B, Port K, Markova AA, et al,. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS ONE 2013; 8: e55285.
14. Hezode C, Fontaine H, Dorival C, et al,. Triple therapy in treatment-experienced patients with hcv-cirrhosis in a multicentre cohort of the french early access programme (anrs co20-cupic)-nct01514890. J Hepatol 2013; 59: 434-41.
15. Vermehren J, Aghemo A, Pfeiffer KH, et al,. Undetectable HCV-RNA in telaprevir-treated patients: low concordance between two highly sensitive real-time pcr assays. J Hepatol 2013; 58 (Suppl.): 208.